Bioequivalence study of a fixed dose combination of nitazoxanide and ofloxacin in Indian healthy volunteers

被引:0
|
作者
Agarwal, Sangita [1 ]
Solomon, W. D. Sam [1 ]
Gowda, K. Veeran [1 ]
Selvan, P. Senthamil [1 ]
Ghosh, Debotri [1 ]
Sarkar, Amlan Kand [1 ]
Chattaraj, Tapas Kumar [1 ]
Pal, Tapan Kumar [1 ]
机构
[1] Jadavpur Univ, Bioequivalence Study Ctr, Dept Pharmaceut Technol, Kolkata 700032, W Bengal, India
来源
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH | 2007年 / 57卷 / 10期
关键词
antibiotics; antiparasitic drugs; CAS; 55981-09-4; 82419-36-1; nitazoxanide; active metabolite; bioavailability; bioequivalence; fixed dose combination; ofloxacin;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Objective. The pharmacokinetics of nitazoxanide (CAS 55981-09-4) and ofloxacin (CAS 82419-36-1) has been extensively evaluated in adult human volunteers individually after oral administration of tablet formulation. However, no published data is available regarding the combined pharmacokinetics and bioavailability of this particular fixed dose combination. In light of the above, a clinical study was designed to evaluate the bioequivalence of two fixed dose combination (FDC) products of two manufacturers containing nitazoxanide 500 mg and ofloxacin 200 mg in healthy Indian male volunteers. Methods: 24 healthy male volunteers (age 25 +/- 4.6 years; weight 74.5 +/- 7.87 kg) were enrolled in this study. Each subject received a Test fixed dose combination and a Reference fixed dose combination formulation in a randomized, single dose, fasting state, two period, crossover study design with a 1-week washout period between the doses. Extraction of the drugs from the plasma was carried out by precipitation method. Analysis of tizoxanide (active metabolite of nitazoxanide) and ofloxacin from plasma samples was done by a simple and sensitive HPLC method using IN detection developed in our laboratory. An analysis of variance was performed on the pharmacokinetic parameters C-max, AUC(0-t), AUC(0-infinity) using general linear model (GLM) procedures in which sources of variation were subject, formulation, period. Results. The results of this investigation indicated that there were no statistically significant differences between the two products in either the mean concentration-time profiles or in the obtained pharmacokinetic parameters. 90% confidence limits for the log-transformed data of C-max, AUC(0-t), AUC(0-infinity). were within the acceptable range of 0.80-1.25. Conclusion: Thus, these findings clearly indicate that the two products are bioequivalent in terms of rate and extent of drug absorption. Both the preparations were well tolerated with no adverse reactions seen throughout the study.
引用
收藏
页码:679 / 683
页数:5
相关论文
共 50 条
  • [1] Pharmacokinetics and Bioequivalence Study of a Fixed Dose Combination of Rabeprazole and Itopride in Healthy Indian Volunteers
    Sahoo, Bijay Kumar
    Das, Ayan
    Agarwal, Sangita
    Bhaumik, Uttam
    Bose, Anirbandeep
    Ghosh, Debotri
    Roy, Bikash
    Pal, Tapan Kumar
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2009, 59 (09): : 451 - 454
  • [2] Bioequivalence Study of Two Fixed Dose Combination Tablet Formulations of Lopinavir and Ritonavir in Healthy Volunteers
    Chachad, Siddarth
    Lulla, Amar
    Malhotra, Geena
    Purandare, Shrinivas
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2009, 59 (05): : 263 - 268
  • [3] Bioequivalence study of a fixed dose combination tablet containing rabeprazole and diclofenac sodium in healthy Indian subjects
    Mukherjee, Jayanti
    Das, Ayan
    Chakrabarty, Uday S.
    Sahoo, Bijay
    Sengupta, Pinaki
    Chatterjee, Bappaditya
    Roy, Bikash
    Pal, Tapan K.
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2010, 60 (08): : 506 - 509
  • [4] Comparative Bioequivalence Study of Leflunomide Tablets in Indian Healthy Volunteers
    Agarwal, S.
    Das, A.
    Ghosh, D.
    Sarkar, A. K.
    Chattaraj, T. K.
    Pal, T. K.
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2012, 62 (03): : 145 - 148
  • [5] Bioequivalence study of a sustained release fixed dose combination capsule containing esomeprazole and domperidone in healthy subjects
    Agarwal, Sangita
    Gowda, Kadajji Veeran
    Mandal, Uttam
    Ghosh, Debotri
    Bose, Anirbandeep
    Sarkar, Amlan Kanti
    Chattaraj, Tapas Kumar
    Pal, Tapan Kumar
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2007, 57 (05): : 274 - 277
  • [6] BIOEQUIVALENCE STUDY OF FIXED DOSE COMBINATION TABLET CONTAINING LORNOXICAM AND THIOCOLCHICOSIDE IN HEALTHY SUBJECTS
    Agarwal, S.
    Das, A.
    Chowhury, H. R.
    Sarkar, A. K.
    Chattaraj, T. K.
    Pal, T. K.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2011, 2 (10): : 2718 - 2723
  • [7] Bioequivalence Evaluation of a Fixed Dose Combination Lamivudine plus Stavudine Tablet with Concurrent Administration of Lamivudine Tablet and Stavudine Capsule in Healthy Volunteers
    Chachad, Siddarth
    Lulla, Amar
    Malhotra, Geena
    Purandare, Shrinivas
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2009, 59 (10): : 537 - 540
  • [8] Bioequivalence study of dihydroartemisinin-piperaquine (DHP) generic formulation in fixed-dose combination, in healthy Indonesian volunteers
    Isnawati, Ani
    Gitawati, Retno
    Raini, Mariana
    Rooslamiati, Indri
    Marliany, Lanny
    Setiawaty, Effi
    Setiawaty, Vivi
    BALI MEDICAL JOURNAL, 2018, 7 (02) : 290 - 295
  • [9] Bioequivalence study of fixed pose combination of atorvastatin and ezetimibe tablet in healthy volunteers by LC-MS/MS method
    Gowda, K. Veeran
    Rajan, D. Senthil
    Mandal, U.
    Solomon, W. D. Sam
    Selvan, P. Senthamil
    Bose, A.
    Sarkar, A. K.
    Chattaraj, T. K.
    Pal, T. K.
    ASIAN JOURNAL OF CHEMISTRY, 2007, 19 (02) : 1293 - 1300
  • [10] Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects
    Kang, Woo Youl
    Seong, Sook Jin
    Ohk, Boram
    Gwon, Mi-Ri
    Kim, Bo Kyung
    Cho, Seungil
    Shim, Wang-Seob
    Lee, Kyung-Tae
    Kim, Eun Hee
    Yang, Dong Heon
    Lee, Hae Won
    Yoon, Young-Ran
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 3607 - 3615